Clinical trialNCT06810544RecruitingPhase 1/PHASE2Interventional

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

SponsorTango Therapeutics, Inc.Enrollment191Brain TumorGlioma Glioblastoma MultiformeGlioma, MalignantLung CancerNon Small Cell Lung CancerNon-Small Cell Adenocarcinoma+1 more conditions

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Tab Cooney, MD
Tango Therapeutics, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic Scottsdale
Scottsdale, Arizona, United States
Mitesh Borad, MD
Recruiting
University of California, Irvine
Irvine, California, United States
Cathleen Park, MD
Recruiting
University of California Los Angeles
Los Angeles, California, United States
Timothy Cloughesy, MD
Recruiting
University of California at San Francisco
San Francisco, California, United States
Nicolas Butowski, MD
Recruiting
Sibley Memorial Hospital
Washington D.C., District of Columbia, United States
Solmaz Sahebjam, MD
Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
Hani Babiker, MD
Recruiting
Northwestern Memorial Hospital
Chicago, Illinois, United States
Ditte Primdahl, MD
Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Jia Luo, MD
Recruiting
Mayo Clinic Cancer Center
Rochester, Minnesota, United States
Kaushal Parikh, MD
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Lauren Schaff, MD
Recruiting
Nyu Langone Health
New York, New York, United States
Salman Punekar, MD
Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Dwight Owen, MD
Recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Jordi Rodon, MD
Recruiting
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, United States
Howard Coleman, MD
Recruiting
Next Virginia
Fairfax, Virginia, United States
Alexander Spira, MD, PhD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

N-(4-amino-1H-pyrazolo[4,5-c]pyridin-7-yl)-N'-methyl-N'-[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl]oxamideAbemaciclib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Mar 2025
Primary completion: 31 Mar 2027
Completion: 30 Sept 2027
Last update posted: 13 Apr 2026
Registered enrollment: 191
Registry id: NCT06810544

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.